EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Loss of tolerance precedes triggering and lifelong persistence of pathogenic type I interferon autoantibodies

Sonja Fernbach iD, Nina K Mair iD, Irene A Abela iD, Kevin Groen iD, Roger Kuratli iD, Marie Lork iD, Christian W Thorball iD, Enos Bernasconi iD, Paraskevas Filippidis iD, Karoline Leuzinger iD, Julia Notter iD, Andri Rauch iD und 7 weitere

Journal of Experimental Medicine · 02.09.2024 · 221 (9)

DOI: 10.1084/jem.20240365 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Experimental Medicine, online erschienen am 17.07.2024. Verfasst von Sonja Fernbach und 18 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Medical Virology, University of Zurich , Zurich, Switzerland. Hauptthemen laut MEDLINE: Autoantibodies, Interferon Type I, COVID-19, Antibodies, Neutralizing. Die Arbeit wurde bisher 52-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swiss National Science Foundation, Novartis Foundation for Medical-Biological Research, Promedica Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Autoantibodies neutralizing type I interferons (IFN-Is) can underlie infection severity. Here, we trace the development of these autoantibodies at high-resolution using longitudinal samples from 1,876 well-treated individuals living with HIV over a 35-year period. Similar to general populations, ∼1.9% of individuals acquired anti-IFN-I autoantibodies as they aged (median onset ∼63 years). Once detected, anti-IFN-I autoantibodies persisted lifelong, and titers increased over decades. Individuals developed distinct neutralizing and non-neutralizing autoantibody repertoires at discrete times that selectively targeted combinations of IFNα, IFNβ, and IFNω. Emergence of neutralizing anti-IFNα autoantibodies correlated with reduced baseline IFN-stimulated gene levels and was associated with subsequent susceptibility to severe COVID-19 several years later. Retrospective measurements revealed enrichment of pre-existing autoreactivity against other autoantigens in individuals who later developed anti-IFN-I autoantibodies, and there was evidence for prior viral infections or increased IFN at the time of anti-IFN-I autoantibody triggering. These analyses suggest that age-related loss of self-tolerance prior to IFN-I immune-triggering poses a risk of developing lifelong functional IFN-I deficiency.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AutoantibodiesInterferon Type ICOVID-19Antibodies, NeutralizingHumansMiddle AgedMaleFemaleAdultAgedSARS-CoV-2HIV InfectionsInterferon-alphaRetrospective Studies

Substanzen

AutoantibodiesInterferon Type IAntibodies, NeutralizingInterferon-alpha

Autor:innen und Institutionen

  • Institute of Medical Virology, University of Zurich , Zurich, Switzerland.
  • Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
  • Precision Medicine Unit, Lausanne University Hospital and University of Lausanne , Lausanne, Switzerland.
  • Division of Infectious Diseases, Ente Ospedaliero Cantonale Lugano, University of Geneva and University of Southern Switzerland, Lugano, Switzerland.
  • Department of Medicine, Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
  • Clinical Virology, University Hospital Basel , Basel, Switzerland.

ORCID-Profile: Sonja Fernbach, Nina K Mair, Irene A Abela, Kevin Groen, Roger Kuratli, Marie Lork, Christian W Thorball, Enos Bernasconi, Paraskevas Filippidis, Karoline Leuzinger, Julia Notter, Andri Rauch, Hans H Hirsch, Michael Huber, Huldrych F Günthard, Jacques Fellay, Roger D Kouyos, Benjamin G Hale

Förderung

  • Swiss National Science Foundation
  • Novartis Foundation for Medical-Biological Research
  • Promedica Foundation

Zitieren

APA

Fernbach, S., Mair, N. K., Abela, I. A., Groen, K., Kuratli, R., Lork, M., Thorball, C. W., Bernasconi, E., Filippidis, P., Leuzinger, K., Notter, J., Rauch, A., Hirsch, H. H., Huber, M., Günthard, H. F., Fellay, J., Kouyos, R. D., Hale, B. G., & Swiss HIV Cohort Study (2024). Loss of tolerance precedes triggering and lifelong persistence of pathogenic type I interferon autoantibodies. Journal of Experimental Medicine, 221(9). https://doi.org/10.1084/jem.20240365

Vancouver

Fernbach S, Mair NK, Abela IA, Groen K, Kuratli R, Lork M, et al. Loss of tolerance precedes triggering and lifelong persistence of pathogenic type I interferon autoantibodies. Journal of Experimental Medicine. 2024;221(9). doi:10.1084/jem.20240365

BibTeX
@article{Fernbach2024,
  author = {Fernbach, Sonja and Mair, Nina K and Abela, Irene A and Groen, Kevin and Kuratli, Roger and Lork, Marie and Thorball, Christian W and Bernasconi, Enos and Filippidis, Paraskevas and Leuzinger, Karoline and Notter, Julia and Rauch, Andri and Hirsch, Hans H and Huber, Michael and Günthard, Huldrych F and Fellay, Jacques and Kouyos, Roger D and Hale, Benjamin G and Swiss HIV Cohort Study, Swiss HIV Cohort Study},
  title = {Loss of tolerance precedes triggering and lifelong persistence of pathogenic type I interferon autoantibodies},
  journal = {Journal of Experimental Medicine},
  year = {2024},
  volume = {221},
  number = {9},
  doi = {10.1084/jem.20240365}
}
Kostenlos starten →